Neuronal α‐Synuclein Disease Stage Progression over 5 Years
Movement Disorders · 2025-07 · 40 (7) · 1318-1330
DOI: 10.1002/mds.30191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 30.04.2025. Verfasst von Tanya Simuni und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Disease Progression, alpha-Synuclein, Parkinson Disease, Neurons. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.
Abstract (Originalsprache)
Background
Neuronal α‐synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha‐synuclein (n‐asyn) pathology. The NSD integrated staging system (NSD‐ISS) for research describes progression across the disease continuum as stages 0 to 6.
Objective
The aim was to assess 5‐year longitudinal change in NSD‐ISS in early disease.
Methods
Analysis included a subset of participants from the Parkinson's Progression Markers Initiative (PPMI) enrolled before 2020 as Parkinson's disease (PD) patients, prodromal PD patients, or healthy controls (HC) who met NSD criteria. Staging was defined based on biomarkers of n‐asyn and dopaminergic dysfunction in early stages, clinical features, and severity of functional impairment in stages 3 to 6. Stages were determined annually for 5 years.
Results
Of 576 NSD participants, 494 were enrolled as PD patients, 74 prodromal PD patients, and 8 HCs. At baseline, 24% of participants were stage 2B, 56% Stage 3, 13% stage 4, and less than 5% in other stages. At year 5, the respective percentages for stages 2B to 4 were 11%, 50%, and 34%, indicating progression through NSD stages. Progression was driven by functional impairment in the predominantly motor domain (95%) for stage 2B to 3, increasing degree of nonmotor dysfunction for stages 3 to 4 (46%), and a combination of domains for stages 4 to 5. Initiation of dopaminergic medications led to stage regression in 8% of participants in Stage 3 but 41% in stage 4.
Conclusions
Our analysis supports the utility of NSD‐ISS in defining the stages of disease progression, at least in the early clinical and prodromal stages (2B, 3, or 4), suggesting the value of NSD‐ISS as a potential research tool for drug development. Further research involving preclinical cohorts is a crucial next step. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
- Department of Neurology, Stanford University School of Medicine, Palo Alto, California, USA.
- Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Psychiatry, University of Pennsylvania and the Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelph…
- Department of Neurology, Movement Disorders and Neuromodulation Center, Weill Institute for Neuroscience, University of California, San Francisco, California, USA.
ORCID-Profile: Tanya Simuni, Michael C Brumm, Kathleen L Poston, Daniel Weintraub
Förderung
- Michael J. Fox Foundation for Parkinson's Research
Zitieren
APA
Simuni, T., Gochanour, C., Nair, A. R., Brumm, M. C., Coffey, C., Poston, K. L., Chahine, L. M., Weintraub, D., Tanner, C. M., Gonzalez-Latapi, P., Kopil, C. M., Xiao, Y., Chowdhury, S., Dam, T., Pagano, G., Stephenson, D., Siderowf, A., Dunn, B., Marek, K., & NSD Working Group the Parkinson's Progression Markers Initiative (2025). Neuronal α‐Synuclein Disease Stage Progression over 5 Years. Movement Disorders, 40(7), 1318-1330. https://doi.org/10.1002/mds.30191
Vancouver
Simuni T, Gochanour C, Nair AR, Brumm MC, Coffey C, Poston KL, et al. Neuronal α‐Synuclein Disease Stage Progression over 5 Years. Movement Disorders. 2025;40(7):1318-1330. doi:10.1002/mds.30191
BibTeX
@article{Simuni2025,
author = {Simuni, Tanya and Gochanour, Caroline and Nair, Anuprita R and Brumm, Michael C and Coffey, Christopher and Poston, Kathleen L and Chahine, Lana M and Weintraub, Daniel and Tanner, Caroline M and Gonzalez-Latapi, Paulina and Kopil, Catherine M and Xiao, Yuge and Chowdhury, Sohini and Dam, Tien and Pagano, Gennaro and Stephenson, Diane and Siderowf, Andrew and Dunn, Billy and Marek, Kenneth and NSD Working Group the Parkinson's Progression Markers Initiative, NSD Working Group the Parkinson's Progression Markers Initiative},
title = {Neuronal α‐Synuclein Disease Stage Progression over 5 Years},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {7},
pages = {1318--1330},
doi = {10.1002/mds.30191}
}
EUVIMED